50636-57-2

Usage

Uses

Used in Pharmaceutical Industry:
6(4-BROMOPHENYL)-3(2H)PYRIDAZINONE is used as a pharmaceutical candidate for its anti-inflammatory and antifungal properties. The presence of the bromophenyl group enhances its medicinal properties, making it a promising agent for the development of new drugs targeting inflammation and fungal infections.
Used in Agricultural Industry:
In the agricultural sector, 6(4-BROMOPHENYL)-3(2H)PYRIDAZINONE is utilized as an antifungal agent to protect crops from fungal diseases, thereby improving crop yield and quality.
Used in Organic Synthesis:
6(4-BROMOPHENYL)-3(2H)PYRIDAZINONE serves as a building block in organic synthesis, allowing the creation of more complex molecules with diverse applications. Its unique structure and functional groups make it a valuable component in the synthesis of various organic compounds for different industries.

Upstream product

• 36725-37-8 6-(4-bromophenyl)-4,5-dihydropyridazin-3(2H)-one 
• 1031756-56-5 2-benzylamino-4-(4-bromophenyl)-4-oxobutanoic acid 
• 99-90-1 para-bromoacetophenone 
• 298-12-4 Glyoxilic acid 
• 6340-79-0 4-oxo-4-(4-bromophenyl)butanoic acid 
• 108-86-1 bromobenzene 
• 35338-15-9 (Z)-4-(4-Bromo-phenyl)-4-oxo-but-2-enoic acid ethyl ester 
• 1353682-60-6 ethyl 5-(4-bromophenyl)-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-7-carboxylate 
• 20972-38-7 (E)-4-(4-bromophenyl)-4-oxobut-2-enoic acid 
• 1220109-80-7 2-phenylmercapto-3-(4-bromobenzoyl)propionic acid 

Downstream Products

• 66548-50-3 3-(p-bromophenyl)-6-chloropyridazine 
• 100716-06-1 6-(4-bromophenyl)-2-ethoxycarbonylmethyl-3(2H)-2,3-dihydropyridazin-3-one 
• 923098-74-2 ethyl 2-(3-(4-bromophenyl)-6-oxopyridazin-1(6H)-yl)propanoate 
• 67820-85-3 N'-[6-(4-cyano-phenyl)-5-methyl-pyridazin-3-yl]-hydrazinecarboxylic acid tert-butyl ester 
• 67820-76-2 N'-[6-(4-bromo-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid ethyl ester 
• 67820-95-5 N'-(6-phenyl-pyridazin-3-yl)-hydrazinecarboxylic acid ethyl ester 
• 67821-02-7 4-[4-methyl-6-(N-methyl-hydrazino)-pyridazin-3-yl]-benzonitrile 
• 67820-75-1 N'-[6-(4-cyano-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid ethyl ester 
• 66548-54-7 3-chloro-6-(4-cyano-phenyl)-pyridazine 
• 1177257-69-0 6-(4-bromophenyl)-2-(prop-2-ynyl)pyridazin-3(2H)-one 
• 1177257-68-9 2-allyl-6-(4-bromophenyl)pyridazin-3(2H)-one 
• 922879-75-2 methyl 2-(3-(4-bromophenyl)-6-oxopyridazin-1(6H)-yl)acetate 
• 104106-95-8 2-(3-(4-bromophenyl)-6-oxopyridazin-1(6H)-yl)acetamide 
• 52240-10-5 4-(1,6-dihydro-6-oxo-3-pyridazinyl)benzonitrile 

Relevant academic research and scientific papers

Rhodium(III)-Catalyzed Alkynylation of 4-Arylphthalazin-1(2H)-one Scaffolds via C-H Bond Activation

Selective C–H bond alkynylation toward modular access to material and pharmaceutical molecules is of great desire in modern organic synthesis. Disclosed herein is rhodium(III)-catalyzed selective C–H bond mono-/bialkynylation of 4-aryl phthalazin-1(2H)-one was developed. The silver salt AgSbF6 are demonstrated to play a vital role in promoting the bialkynylation reactions. The present alkynylation strategy is simple, efficient, and features high functional group tolerance and broad substrate scope under an air atmosphere. Additionally, 6-aryl pyridazin-3(2H)-one scaffold is amenable to the selective monoalkynylation and sequential bialkynylation, respectively.

A new series of pyridazinone derivatives as cholinesterases inhibitors: Synthesis, in vitro activity and molecular modeling studies

Background: The pyridazinone nucleus has been incorporated into a wide variety of therapeutically interesting molecules to transform them into better drugs. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are known to be serine hydrolase enzymes responsible for the hydrolysis of acetylcholine (ACh). Inhibition of cholinesterases is an effective method to curb Alzheimer's disease. Here, we prepared 12 new 6-substituted-3(2H)-pyridazinone-2-acetyl-2-(nonsubstituted/4-substituted benzenesulfonohydrazide) derivatives and evaluated their inhibitory effects on AChE/BChE in pursuit of potent dual inhibitors for Alzheirmer's Disease. We also tried to get insights into binding interactions of the synthesized compounds in the active site of both enzymes by using molecular docking approach. Method: We obtained our compounds by the reaction of various substituted/nonsubstituted benzenesulfonic acid derivatives with 6-substitutedphenyl-3(2H)-pyridazinone-2-yl acetohydrazide and determined their anticholinesterase activities according to the Ellman's method. Molecular docking studies were done using Glide and the results were evaluated on Maestro (Schr?dinger, LLC, New York, NY, 2019). Results: The title compounds showed moderate inhibition at 100 μg/ml against both enzymes, yet with better activity against BChE. Compound VI2a emerged as a dual inhibitor with 25.02% and 51.70% inhibition against AChE and BChE, respectively. Conclusion: This study supports that novel pyridazinone derivates may be used for the development of new BChE inhibitory agents. It was less potent than the reference drugs, yet promising for further modifications as a lead. The ability of the compounds to adopt energetically more favourable conformations and to engage in more key interactions in the ECBChE active gorge explains their better activity profile against ECBChE.

Features of reactions of (E)-[(2-aroyl)ethenyl]triphenylphosphonium bromides with binucleophiles

Reactions of (E)-[(2-aroyl)ethenyl]triphenylphosphonium bromides with hydroxylamine hydrochloride resulted in the formation of oximes undergoing α-phenyl migration when reacted with aqueous alkali. Reaction of these salts with hydrazine hydrochloride and

Synthesis and Bioevaluation of 3,6-Diaryl-[1,2,4]triazolo[4,3-b] Pyridazines as Antitubulin Agents

A series of 3,6-diaryl-[1,2,4]triazolo[4,3-b]pyridazines were designed as a class of vinylogous CA-4 analogues. The easily isomerized (Z,E)-butadiene linker of vinylogous CA-4 was replaced by a rigid [1,2,4]triazolo[4,3-b]pyridazine scaffold. Twenty-one target compounds were synthesized and exhibited moderate to potent antiproliferative activity. The compound 4q with a 3-amino-4-methoxyphenyl moiety as the B-ring, comparable to CA-4 (IC50 = 0.009-0.012 μM), displayed the highly active antiproliferative activity against SGC-7901, A549, and HT-1080 cell lines with IC50 values of 0.014, 0.008, and 0.012 μM, respectively. Tubulin polymerization experiments indicated that 4q effectively inhibited tubulin polymerization, and immunostaining assay revealed that 4q significantly disrupted tubulin microtubule dynamics. Moreover, cell cycle studies revealed that compound 4q dramatically arrested cell cycle progression at G2/M phase in A549 cells. Molecular modeling studies showed that 4q could bind to the colchicine binding site on microtubules.

Copper-catalyzed aerobic dehydrogenation of C-C to C=C bonds in the synthesis of pyridazinones

A simple and efficient procedure for the synthesis of pyridazin-3(2H)-ones through copper-catalyzed dehydrogenation of a single C-C bond of 4,5-dihydropyridazin-3(2H)-ones to a C=C bond with oxygen as the terminal oxidant is described. Functional groups including hydroxy, carboxylic, bromo, chloro, cyano, nitro and alkoxy were all tolerated under the reaction conditions. Moreover, this methodology was applied to the preparation of a series of structurally similar N-substituted 6-phenylpyridazinone compounds containing fluorine. The dehydrogenation reactions exhibit good yields and selectivity. Copper-catalyzed dehydrogenation of a C-C bond of 4,5-dihydropyridazinones to a C=C bond with oxygen as the terminal oxidant is described. Various functional groups were tolerated under the reaction conditions. The method was also applied to the preparation of a series of N-substituted 6-phenylpyridazinones containing fluoride. The dehydrogenation reactions exhibit good yields and selectivity.

Reactions of 3-aroylacrylates with α-aminoazoles

Dihydro derivatives of pyrazolo[3,4-b]pyridine-, pyrazolo[1,5-a]pyrimidine- , and [1,2,4]triazolo-[1,5-a]pyrimidinecarboxylates have been prepared by cyclocondensation of β-aroylacrylates with 5-aminopyrazoles and 3-amino-1,2,4-triazole. Heating dihydro[1,2,4]triazolo[1,5-a]pyrimidine-7- carboxylates with hydrazine hydrate led to recyclization of the pyrimidine ring to form 6-arylpyridazin-3(2H)-ones.

Synthesis of some new pyridazin-3-one derivatives and their utility in heterocyclic synthesis

(Chemical Equation Presented) Synthesis of new heterocyclic compounds containing the pyridazinone moiety, which have a valuable biological activities, has been achieved through the nucleophilic addition of benzylamine to 4-(p-substituted phenyl)-4-oxo-2-b

FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.